CONCLUSION
Our study is the first study investigating periostin levels in patients
with COVID-19, and it was found to be significantly higher in patients
with COVID-19. Periostin can be used as a new biomarker; however, we
believe that further studies with larger numbers of cases and longer
follow-up periods are needed for its use in the follow-up and severity
prediction of the disease.